Oramed Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $3.02
- Today's High:
- $3.108
- Open Price:
- $3.04
- 52W Low:
- $1.81
- 52W High:
- $13.73
- Prev. Close:
- $3.04
- Volume:
- 104025
Company Statistics
- Market Cap.:
- $124.45 million
- Book Value:
- 3.768
- Revenue TTM:
- $2.70 million
- Operating Margin TTM:
- -996.23%
- Gross Profit TTM:
- $2.70 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -10.56%
- Return on Equity TTM:
- -13.77%
Company Profile
Oramed Pharmaceuticals Inc had its IPO on 2006-04-21 under the ticker symbol ORMP.
The company operates in the Healthcare sector and Biotechnology industry. Oramed Pharmaceuticals Inc has a staff strength of 0 employees.
Stock update
Shares of Oramed Pharmaceuticals Inc opened at $3.04 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $3.02 - $3.11, and closed at $3.06.
This is a +0.66% increase from the previous day's closing price.
A total volume of 104,025 shares were traded at the close of the day’s session.
In the last one week, shares of Oramed Pharmaceuticals Inc have slipped by -11.05%.
Oramed Pharmaceuticals Inc's Key Ratios
Oramed Pharmaceuticals Inc has a market cap of $124.45 million, indicating a price to book ratio of 2.0879 and a price to sales ratio of 117.9787.
In the last 12-months Oramed Pharmaceuticals Inc’s revenue was $2.70 million with a gross profit of $2.70 million and an EBITDA of $-26807000. The EBITDA ratio measures Oramed Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Oramed Pharmaceuticals Inc’s operating margin was -996.23% while its return on assets stood at -10.56% with a return of equity of -13.77%.
In Q1.6666666666667, Oramed Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Oramed Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.51 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Oramed Pharmaceuticals Inc’s profitability.
Oramed Pharmaceuticals Inc stock is trading at a EV to sales ratio of 60.1121 and a EV to EBITDA ratio of -6.1312. Its price to sales ratio in the trailing 12-months stood at 117.9787.
Oramed Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $156.31 million
- Total Liabilities
- $1.07 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $20000
- Dividend Payout Ratio
- 0%
Oramed Pharmaceuticals Inc ended 2024 with $156.31 million in total assets and $0 in total liabilities. Its intangible assets were valued at $156.31 million while shareholder equity stood at $151.55 million.
Oramed Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $1.07 million in other current liabilities, 484000.00 in common stock, $-167670000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $6.77 million and cash and short-term investments were $150.20 million. The company’s total short-term debt was $236,000 while long-term debt stood at $0.
Oramed Pharmaceuticals Inc’s total current assets stands at $150.97 million while long-term investments were $3.52 million and short-term investments were $143.43 million. Its net receivables were $0 compared to accounts payable of $828000.00 and inventory worth $0.
In 2024, Oramed Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $20000.
Comparatively, Oramed Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $3.06
- 52-Week High
- $13.73
- 52-Week Low
- $1.81
- Analyst Target Price
- $3.15
Oramed Pharmaceuticals Inc stock is currently trading at $3.06 per share. It touched a 52-week high of $13.73 and a 52-week low of $13.73. Analysts tracking the stock have a 12-month average target price of $3.15.
Its 50-day moving average was $3.25 and 200-day moving average was $3.96 The short ratio stood at 2.26 indicating a short percent outstanding of 0%.
Around 1016.8% of the company’s stock are held by insiders while 1035.1% are held by institutions.
Frequently Asked Questions About Oramed Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. The company’s product portfolio includes ORMD-0801 Type 2, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes; ORMD-0801, Phase 2 oral insulin capsule for non-alcoholic steatohepatitis, a progressive liver diseases; and ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.